Paperpal Prime Logo

Clinical and Applied Thrombosis/Hemostasis : Impact Factor & More

eISSN: 1938-2723pISSN: 1076-0296
JournalOpen Access

Key Metrics

CiteScore
4
H-Index
59
Impact Factor
< 5
SJR
Q2Hematology
SNIP
1.05
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Clinical and Applied Thrombosis/Hemostasis

Clinical and Applied Thrombosis/Hemostasis Journal Specifications

Overview
Publisher SAGE PUBLICATIONS INC
Language English
Frequency Continuous publication
Article Processing ChargesUSD 2500
Publication Time8
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year1995
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 8
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC BY-NC
OA statementVisit website
View less

Planning to publish in Clinical and Applied Thrombosis/Hemostasis ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Clinical and Applied Thrombosis/Hemostasis

Enhanced Fibrinolysis in Lung Cancer Patients: A Functional Assessment Using Lysis Slope Time and Fibrinolytic Biomarkers
  • 4 Aug 2026
  • Clinical and Applied Thrombosis/Hemostasis
Pharmacist-Led Discharge Counseling and Adherence to Postpartum Venous Thromboembolism Prophylaxis: A Pre\u2013Post Observational Study
  • 4 Aug 2026
  • Clinical and Applied Thrombosis/Hemostasis
Clinical Impact of Inherited Thrombophilia in Patients With Thrombosis: Evaluating the Real Risk of FVL, PTG20210A, and MTHFR Mutations in the Kurdistan Region of Iraq
  • 3 Aug 2026
  • Clinical and Applied Thrombosis/Hemostasis
Caplacizumab-Enabled Treatment of Immune-Mediated Thrombotic Thrombocytopenic Purpura Without Plasma Exchange: Evidence, Patient Selection, and Practical Considerations
  • 3 Aug 2026
  • Clinical and Applied Thrombosis/Hemostasis
The Triglyceride-glucose Index Predicts Short-Term Mortality in Critically Ill Patients With Cancer-Associated Thrombosis: A Retrospective Cohort Study
  • 3 Aug 2026
  • Clinical and Applied Thrombosis/Hemostasis
Diagnostic Validation of PERC and Resource Utilization in Suspected Acute Pulmonary Embolism: A Systematic Review and Meta-Analysis
  • 1 Aug 2026
  • Clinical and Applied Thrombosis/Hemostasis
Enhanced Fibrinolysis in Lung Cancer Patients: A Functional Assessment Using Lysis Slope Time and Fibrinolytic Biomarkers
  • 4 Aug 2026
  • Clinical and Applied Thrombosis/Hemostasis
Pharmacist-Led Discharge Counseling and Adherence to Postpartum Venous Thromboembolism Prophylaxis: A Pre\u2013Post Observational Study
  • 4 Aug 2026
  • Clinical and Applied Thrombosis/Hemostasis
Clinical Impact of Inherited Thrombophilia in Patients With Thrombosis: Evaluating the Real Risk of FVL, PTG20210A, and MTHFR Mutations in the Kurdistan Region of Iraq
  • 3 Aug 2026
  • Clinical and Applied Thrombosis/Hemostasis
Caplacizumab-Enabled Treatment of Immune-Mediated Thrombotic Thrombocytopenic Purpura Without Plasma Exchange: Evidence, Patient Selection, and Practical Considerations
  • 3 Aug 2026
  • Clinical and Applied Thrombosis/Hemostasis
The Triglyceride-glucose Index Predicts Short-Term Mortality in Critically Ill Patients With Cancer-Associated Thrombosis: A Retrospective Cohort Study
  • 3 Aug 2026
  • Clinical and Applied Thrombosis/Hemostasis
Diagnostic Validation of PERC and Resource Utilization in Suspected Acute Pulmonary Embolism: A Systematic Review and Meta-Analysis
  • 1 Aug 2026
  • Clinical and Applied Thrombosis/Hemostasis

FAQs on Clinical and Applied Thrombosis/Hemostasis